1. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. (24th December 2020) Authors: Claudiani, Simone; Apperley, Jane F.; Szydlo, Richard; Khan, Afzal; Nesr, George; Hayden, Chloe; J. Innes, Andrew; Dominy, Kathy; Foskett, Pierre; Foroni, Letizia; Khorashad, Jamshid; Milojkovic, Dragana Journal: British journal of haematology Issue: Volume 193:Number 2(2021) Page Start: 346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗